Clinical and economic outcomes by first-line treatment among women with HR+/HER2-metastatic breast cancer in a large US health plan database.

CONCLUSIONS: Observed use of first-line chemotherapy (>50%) was higher than expected given the HR+ molecular profile of the tumors. Chemotherapy use during first-line did not appear to be associated with a survival benefit but was associated with significantly higher costs compared with the use of hormonal therapy during first-line; however, this comparison is limited by demographic and baseline characteristic differences between the 2 cohorts. This study contributes to understanding real-world treatment patterns and the associated clinical and economic outcomes of using chemotherapy versus hormonal therapy as a first-line treatment option for the HR+/HER2- mBC population. PMID: 27074160 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research